When you look at the volume on the 3y chart, there's something striking; the low volume lately.
At this stage (45% into the pivotal Ph. 2), longs are not selling any. So if one wants in, in volume, the stock price lifts. If upcoming results show a very convincing high efficacy trend, then the stock price will also lift. And shorting this stock is suicidal at this time.
Efficacy data from the optimized group will be very interesting to watch, especially those ones:
The maintenance study treatment has been provided to 15 patients, with 11 maintenance study treatments pending (@270 days).